tadalafil has been researched along with sildenafil in 24 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (sildenafil) | Trials (sildenafil) | Recent Studies (post-2010) (sildenafil) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 134 | 0 | 60 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 11 (45.83) | 24.3611 |
| 2020's | 3 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Adam, L; Beyer, B; Chong, S; Ferrer, P; He, B; Henwood, A; Humphrey, WG; Krupinski, J; Macor, JE; Mason, H; Normandin, D; Pongrac, R; Seliger, L; Wang, J; Wu, X; Yu, G; Zhang, R | 1 |
| Coste, H; Daugan, A; Grondin, P; Hyafil, F; Kirilovsky, J; Labaudinière, R; Le Monnier de Gouville, AC; Linget, JM; Ruault, C | 1 |
| Artis, DR; Bollag, G; Card, GL; England, BP; Fong, D; Gillette, S; Ibrahim, PN; Kim, SH; Lee, B; Luu, C; Milburn, MV; Powell, B; Schlessinger, J; Suzuki, Y; Tabrizizad, M; Zhang, KY | 1 |
| Bhattacharjee, S; Guan, J; Haynes-Johnson, D; Jiang, W; John, TM; Kraft, P; Lundeen, S; Macielag, MJ; Qiu, Y; Sui, Z; Zhang, S | 1 |
| Asberom, T; Boyle, CD; Chackalamannil, S; Chintala, M; Clader, JW; Greenlee, WJ; Guzik, H; Hu, Y; Hu, Z; Kurowski, S; Lankin, CM; Myers, J; Palamanda, J; Pissarnitski, DA; Skell, J; Stamford, AW; Vemulapalli, S; Wang, P; Wang, Y; Wu, P; Xu, R | 1 |
| Cesari, N; Dal Piaz, V; Feixas, J; Gavaldà, A; Giovannoni, MP; Graziano, A; Vergelli, C | 1 |
| Hughes, RA; Manallack, DT; Thompson, PE | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Antunes, JE; da Cunha, EF; Freitas, MP; Ramalho, TC; Rittner, R | 1 |
| Ahn, SK; Choi, H; Choi, NS; Han, CK; Hwang, IC; Im, DS; Kim, SJ; Kim, SW; Kim, YH; Lee, HW; Lee, J; Lee, KJ; Lee, SS; Moon, SK; Yoon, JH | 1 |
| Ahn, SK; Choi, H; Choi, NS; Hwang, IC; Im, DS; Kim, SJ; Kim, SW; Kim, YH; Lee, HW; Lee, J; Lee, KJ; Lee, SS; Moon, SK | 1 |
| Arancio, O; Deng, SX; Feng, Y; Fiorito, J; Francis, YI; Landry, DW; Rao, S; Saeed, F; Staniszewski, A; Thakkar, DM; Zhang, H | 1 |
| Fujishige, K; Hikota, M; Kikkawa, K; Koga, Y; Kotera, J; Matsuki, K; Morimoto, H; Murakami, M; Omori, K; Sakamoto, T; Yamada, K | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cuadrado-Tejedor, M; de Miguel, I; Espelosin, M; Estella-Hermoso de Mendoza, A; García-Barroso, C; Garcia-Osta, A; Haizhong, T; Musheng, X; Oyarzabal, J; Pérez-González, M; Rabal, O; Sáez, E; Sánchez-Arias, JA; Ugarte, A; Ursua, S; Wei, W | 2 |
| Huang, YY; Li, Z; Luo, HB; Wu, D; Wu, Y | 1 |
| Leeson, PD; Young, RJ | 1 |
| Chen, J; Chen, Y; Geng, H; Guo, L; Huang, Y; Huang, YY; Li, Z; Luo, HB; Wu, D; Zhang, C; Zhang, T | 1 |
| Cheng, C; Jiang, Y; Lou, H; Qiao, Y; Sun, B; Tan, J; Wu, Y; Xie, Z; Zhao, S; Zheng, H | 1 |
| Aisa, HA; Gong, X; He, Y; Jiang, H; Jiang, X; Li, J; Liu, Z; Shen, J; Shi, J; Suo, J; Tian, G; Wang, Y; Wang, Z; Wu, C; Wu, J; Xu, Y; Xu, Z; Yang, R; Yang, X; Zhang, R; Zhang, X; Zhu, W; Zou, X | 1 |
| Dong, YH; Huang, XF; Ke, HM; Song, GQ; Wang, JH; Xu, DF | 1 |
| Abadi, AH; Abdel-Halim, M; Engel, M; Fathalla, RK; Hammam, MA; Hartmann, RW; Hefnawy, A; Keeton, AB; Maher, A; Maxuitenko, Y; Piazza, GA; Racheed, NAS; Sigler, S | 1 |
| Chai, S; Chen, S; Deng, L; Du, K; Shen, R; Sun, H; Sun, T; Xi, M; Xie, M | 1 |
5 review(s) available for tadalafil and sildenafil
| Article | Year |
|---|---|
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
Topics: Animals; Binding Sites; Crystallography, X-Ray; Cyclic AMP; Cyclic GMP; Drug Design; Humans; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Quantitative Structure-Activity Relationship; Xanthines | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Cognition; Humans; Phosphodiesterase Inhibitors | 2018 |
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.
Topics: Animals; Chemical Phenomena; Drug Discovery; Humans; Hydrophobic and Hydrophilic Interactions | 2018 |
Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Alzheimer Disease; Animals; Cognition; Cyclic GMP; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases | 2022 |
19 other study(ies) available for tadalafil and sildenafil
| Article | Year |
|---|---|
Substituted pyrazolopyridopyridazines as orally bioavailable potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Administration, Oral; Animals; Biological Availability; Blood Pressure; Cyclic Nucleotide Phosphodiesterases, Type 5; Dogs; Enzyme Inhibitors; Erectile Dysfunction; Female; Male; Penis; Pyridazines; Rabbits; Rats; Structure-Activity Relationship | 2003 |
The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Pressure; Carbolines; Cattle; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Hydantoins; Indicators and Reagents; Isomerism; Models, Molecular; Molecular Conformation; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Rats; Rats, Inbred SHR; Structure-Activity Relationship; Tadalafil | 2003 |
Structural basis for the activity of drugs that inhibit phosphodiesterases.
Topics: Binding Sites; Crystallography, X-Ray; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Protein Structure, Tertiary | 2004 |
Pyrroloquinolone PDE5 inhibitors with improved pharmaceutical profiles for clinical studies on erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Biological Availability; Blood Pressure; Cell Line; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Dogs; Electric Stimulation; Erectile Dysfunction; Macaca mulatta; Male; Penis; Pyrroles; Quinolones; Rats; Rats, Sprague-Dawley; Solubility; Stereoisomerism; Structure-Activity Relationship | 2005 |
Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Male; Models, Molecular; Molecular Structure; Phosphodiesterase I; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Rats; Sildenafil Citrate; Structure-Activity Relationship; Sulfones; Vasodilator Agents | 2005 |
New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Blood Platelets; Cattle; Cyclic Nucleotide Phosphodiesterases, Type 5; Cyclic Nucleotide Phosphodiesterases, Type 6; Molecular Structure; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyrazoles; Pyridazines; Retina; Sensitivity and Specificity; Structure-Activity Relationship | 2005 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil.
Topics: Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Imidazoles; Mice; Models, Molecular; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Quantitative Structure-Activity Relationship; Rats; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2008 |
Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.
Topics: Combinatorial Chemistry Techniques; Erectile Dysfunction; Humans; Male; Molecular Structure; Penile Erection; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Quinazolines; Structure-Activity Relationship | 2008 |
Discovery of potent, selective, and orally bioavailable PDE5 inhibitor: Methyl-4-(3-chloro-4-methoxybenzylamino)-8-(2-hydroxyethyl)-7-methoxyquinazolin-6-ylmethylcarbamate (CKD 533).
Topics: Administration, Oral; Animals; Carbamates; Catalytic Domain; Computer Simulation; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Enzyme Inhibitors; Erectile Dysfunction; Humans; Male; Microsomes, Liver; Phosphodiesterase 5 Inhibitors; Quinazolines; Rabbits; Rats | 2010 |
Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Drug Discovery; Female; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Phosphodiesterase 5 Inhibitors; Quinolines | 2013 |
The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor.
Topics: Animals; Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Pyrimidines; Rabbits | 2014 |
Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.
Topics: Acetylation; Alzheimer Disease; Animals; Cell Line; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Models, Molecular; Phosphodiesterase 5 Inhibitors | 2016 |
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Line; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Drug Design; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Molecular Structure; Neuroglia; Phosphodiesterase 5 Inhibitors; Structure-Activity Relationship | 2018 |
Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.
Topics: Administration, Oral; Animals; Crystallography, X-Ray; ERG1 Potassium Channel; Hypertension, Pulmonary; Microsomes, Liver; Models, Molecular; Molecular Structure; Phosphodiesterase 5 Inhibitors; Protein Conformation; Pulmonary Artery; Structure-Activity Relationship | 2018 |
Discovery of furyl/thienyl β-carboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect.
Topics: Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Female; Humans; Male; Mesenteric Arteries; Molecular Docking Simulation; Phosphodiesterase 5 Inhibitors; Rats, Wistar; Structure-Activity Relationship; Vasodilator Agents | 2018 |
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.
Topics: Animals; Dogs; Drug Design; Female; Half-Life; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Sildenafil Citrate; Structure-Activity Relationship; Substrate Specificity | 2019 |
Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinergic Antagonists; Cognitive Dysfunction; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Indole Alkaloids; Mice; Models, Molecular; Molecular Structure; Morris Water Maze Test; Phosphodiesterase 5 Inhibitors; Protein Conformation; Quinazolines; Scopolamine | 2020 |
From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.
Topics: Animals; Blood Proteins; Celecoxib; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Design; Female; Half-Life; Humans; Isoenzymes; Mice; Mice, Inbred C57BL; Microsomes, Liver; Phosphodiesterase 5 Inhibitors; Protein Binding; Pyrazoles; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship | 2021 |